A few minutes earlier, at 4:30 PM ET, Accolade (NASDAQ: ACCD) reported their Q3 2022. The company – now trading at $19.37, with a -64.67% decrease in price in the last six months – has beaten the EPS Estimated and the Revenue Estimated. The Actual EPS reported is -$0.31 against the -$0.63 estimated and with Revenue during the quarter of $83.5M against an estimated $75.89M (+97.4% Y/Y).
During the earnings call, the company provided a preliminary forecast for the fiscal year 2023, anticipating a 25% increase in sales.
The company has constantly missed the EPS Estimated during the last three earnings reports with a -12.64% surprise on Q2 2022, reported on Oct 7th. On the other side, Accolade has beaten the Expected Revenues during the last three earning reports exceeding expectations by 4.15% during the Q2 2022.
During the Q3 2022 earnings call, the management highlighted an effort to acquire more clients in Accolade Care virtual primary care and launch in full-scale Accolade One, a full-service offering. In addition, Singh, the CEO, highlighted how the company’s customized health care solutions approach is the key to the next generation of health care services.
ACCD that went public on July 2nd, 2020, has lost over 64% in the last six months, trading $19.38 at market close. After posting Q3 2022, Accolade stock is up by 13.38% in post-market trading.
The Accolade mission
Accolade aims to make healthcare more personalized for employers and employees.
Their goal is to improve healthcare outcomes by providing more tailored care focused on what people need. Accolade has three different offerings, mainly targeting companies rather than individuals.
The first is the Disease Management Program which consists of an annual physical evaluation for employees, plus customized interventions if they are found to have an illness. The second is the Health Risk Assessment Program which helps employees take charge of their health by identifying risks and providing prevention tips. And finally, the Wellness Program offers small group classes in yoga, strength training, and career coaching to put employees in the best position possible to succeed in all aspects of life.
Accolade is an innovative healthcare company founded on the idea of personalized care. They believe that each person is unique and deserves to be treated as such. That’s why Accolade offers a range of options for personalized healthcare. From cosmetic surgery for men and women to weight loss programs, Accolade has it all.
Accolade shows that personalized healthcare is an achievable goal that aims to diagnose and treat each individual with care tailored to their unique needs. This often includes genetic testing, psychotherapy, or medical devices.
Personalized healthcare is the next frontier in medicine.
Personalized medicine has already improved the way we diagnose and treat disease. The health care industry is rapidly changing to meet the needs of a digital, data-driven world. For example, hospitals use phenotyping to design better-personalized treatments for patients, while doctors administer cancer treatments based on genetic information previously impossible to collect or analyze.
These are just some ways that personalized healthcare is helping us live healthier lives. With the digitization of our lives, doctors are designing more personalized treatments for patients by collecting data and delivering it back to them.
In general, healthcare stocks are still a popular investment option, as they are seen as less volatile than other sectors. It’s also believed that the aging population will continue to place increasing demand on healthcare services. The healthcare industry is a multi-trillion dollar industry that continues to grow. Healthcare costs are rising, and the need for high-quality care is increasing.